title: Effects of U50,488, a selective kappa agonist, on atypical mouse opiate systems.
abstract: We have proposed that endogenous opioids play a critical role in the etiology of anorexia nervosa, mediating an auto-addiction, and that atypical opioid systems in mice may be representative of those in anorexia nervosa patients, in contrast to normal humans and rats. A biological predisposition to eating disorders may result from these atypical opioid systems. Definition of these systems as atypical is based on their responses to morphine, which are preferential for the mu receptor subtype. Three patterns have been described in four strains of mice: anorexia with hyperactivity (BALB/C and C57BL/J), anorexia without hyperactivity (DBA/J), and a biphasic curve (CF-1). The latter showed anorexia and hyperactivity at high doses but increased food intake without a change in motor activity at low doses. These patterns contrast to the increase in food intake and sedation in typical species, including rats and normal humans. In the present study, U50,488, a selective kappa agonist, increases food intake in all four mouse strains, as previously reported in rats. Thus, these two agonists have opposite effects on the atypical mouse systems, but similar effects on the typical rat system. The typical and atypical opioid systems respond oppositely to morphine but similarly to U50,488.
authors.affiliation: Department of Pharmacology, Wayne State University, School of Medicine, Detroit, MI 48201.
authors.forename: M A
authors.initials: MA
authors.lastname: Marrazzi
authors.forename: J
authors.initials: J
authors.lastname: Lawhorn
authors.forename: V
authors.initials: V
authors.lastname: Graham
authors.forename: D
authors.initials: D
authors.lastname: L'Abbe
authors.forename: J
authors.initials: J
authors.lastname: Mullings-Britton
authors.forename: L
authors.initials: L
authors.lastname: Stack
authors.forename: T
authors.initials: T
authors.lastname: Eccles
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000855:Anorexia / Q000503:physiopathology*; D004435:Eating / Q000187:drug effects / Q000502:physiology; D004723:Endorphins / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009020:Morphine / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects / Q000502:physiology*; D017473:Receptors, Opioid, kappa
chemical_list: D000700:Analgesics; D004723:Endorphins; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D009020:Morphine